Vivani Medical Advances with LIBERATE-1 Clinical Trial

An announcement from Vivani Medical ( (VANI) ) is now available.

On March 12, 2025, Vivani Medical announced plans to spin off its Cortigent neurostimulation business into an independent, publicly traded company by mid-2025, subject to certain conditions. This strategic move aims to create two focused companies, allowing Vivani to concentrate on its NanoPortal drug implants, while Cortigent will continue developing neurostimulation technologies for vision and stroke recovery. On March 13, 2025, Vivani also reported the successful first implant and full enrollment in its LIBERATE-1 clinical trial for the GLP-1 implant NPM-115, targeting medication adherence in chronic weight management and type 2 diabetes. The trial’s top-line results are expected by mid-2025, potentially transforming treatment options for these conditions.

More about Vivani Medical

Vivani Medical, Inc. is a clinical-stage biopharmaceutical company that develops miniature, ultra long-acting drug implants using its proprietary NanoPortal™ platform. The company focuses on delivering drug molecules steadily over extended periods to improve medication adherence and patient tolerance. Vivani’s lead program, NPM-115, is a subdermal GLP-1 implant for chronic weight management. Cortigent, Inc., formerly Second Sight Medical Products and a wholly-owned subsidiary of Vivani, is a leader in precision neurostimulation technology, developing brain implant devices for critical body functions recovery, including artificial vision for the blind.

YTD Price Performance: -13.33%

Average Trading Volume: 99,404

Technical Sentiment Consensus Rating: Buy

Current Market Cap: $62.2M

For detailed information about VANI stock, go to TipRanks’ Stock Analysis page.